With early HIV vaccine results announced Monday, Johnson & Johnson and its partners hope they might have a winner.

VBI Vaccines hopes to challenge the hepatitis B vaccine standard-of-care, a position long held by GlaxoSmithKline’s Engerix-B.

While GSK is still expected to top the vaccine industry in 2022, rankings for other players have shifted in Evaluate's new World Preview.

Chasing a $6 billion market opportunity, Bavarian Nordic reports that a dose of its universal RSV vaccine can elicit a significant immune response.

Declining sales of Prevnar have urged Pfizer to seek compensation elsewhere, including a vaccine against Group B streptococcus.

BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.

Scientists at the University of Maryland, hoping to fill the hepatitis vaccine void, have secured funding from the NIH to work on a new candidate.

Merck & Co. may not be number one with a bullet in vaccines, but CEO Ken Frazier says the unit shouldn't be underestimated.